Glenmark Pharmaceuticals Sees Notable Surge in Derivatives Open Interest Amid Stable Price Action

Open Interest and Volume Dynamics

On 19 Feb 2026, Glenmark’s open interest rose from 44,013 contracts to 48,593 contracts, marking an increase of 4,580 contracts or 10.41%. This expansion in OI is significant, especially given the stock’s underlying price of ₹2,034. The futures segment alone accounted for a value of approximately ₹1,11,207 lakhs, while options contributed a staggering ₹10,665 crores in notional value, culminating in a total derivatives value exceeding ₹1,12,183 lakhs. The daily traded volume stood at 28,216 contracts, reflecting robust participation in the derivatives market.

Such a rise in open interest, alongside sustained volume, typically indicates that new positions are being established rather than closed out. This can be interpreted as fresh capital entering the market, with investors either initiating bullish or bearish bets depending on their outlook.

Price and Moving Average Context

Despite the surge in derivatives activity, Glenmark’s stock price remained largely stable, with a marginal day change of 0.03%. The stock is trading comfortably above its key moving averages — 5-day, 20-day, 50-day, 100-day, and 200-day — signalling an underlying bullish technical setup. This technical strength suggests that the open interest increase may be driven by investors positioning for a potential upward move, even as the broader market, represented by the Sensex, declined by 1.12% on the same day.

Sector-wise, Glenmark’s performance was inline with the Pharmaceuticals & Biotechnology sector, which saw a modest 0.16% decline. The stock’s one-day return was a slight negative 0.09%, indicating relative resilience amid sectoral weakness.

Investor Participation and Liquidity Considerations

Interestingly, delivery volumes on 18 Feb 2026 fell by 15.37% compared to the five-day average, with 1.93 lakh shares delivered. This decline in physical investor participation contrasts with the rising derivatives activity, suggesting that traders may be favouring synthetic exposure through futures and options rather than outright stock purchases.

Liquidity remains adequate for sizeable trades, with the stock’s average traded value supporting transactions up to ₹1.98 crore based on 2% of the five-day average traded value. This liquidity profile supports active derivatives trading without significant market impact.

Market Positioning and Directional Bets

The increase in open interest, combined with stable prices and strong technicals, points to a growing conviction among traders that Glenmark Pharmaceuticals may be poised for an upward trajectory. The stock’s Mojo Score of 78.0 and a current Mojo Grade of Buy, recently downgraded from Strong Buy on 6 Jun 2025, reflect a cautious but positive outlook from MarketsMOJO’s quantitative models.

Given the pharmaceutical sector’s defensive qualities and Glenmark’s mid-cap status with a market capitalisation of ₹57,238.79 crore, investors may be positioning for a sectoral rebound or company-specific catalysts such as new drug launches, regulatory approvals, or earnings upgrades. The derivatives market activity suggests that participants are increasingly using options and futures to leverage their views, possibly employing strategies like long calls or bull call spreads to capitalise on anticipated gains while managing risk.

Comparative Sector and Benchmark Analysis

While the Sensex declined by 1.12% and the Pharmaceuticals & Biotechnology sector dipped 0.16%, Glenmark’s near-flat price movement and rising derivatives interest indicate relative strength. This divergence may attract momentum traders and institutional investors seeking mid-cap opportunities with solid fundamentals and technical support.

Moreover, the stock’s trading above all major moving averages underscores a sustained uptrend, which could encourage further accumulation in both cash and derivatives markets.

Implications for Investors

For investors, the surge in open interest in Glenmark’s derivatives signals an opportunity to reassess portfolio exposure. The stock’s technical strength and relative outperformance within its sector suggest that it could be a candidate for accumulation, particularly for those with a medium to long-term horizon.

However, the recent downgrade from Strong Buy to Buy by MarketsMOJO on 6 Jun 2025 advises a measured approach, factoring in potential volatility and sector-specific risks such as regulatory changes or competitive pressures. The decline in delivery volumes also hints at a shift towards trading rather than investing, which may increase short-term price fluctuations.

Overall, the derivatives market activity provides valuable insight into market sentiment and positioning, highlighting Glenmark Pharmaceuticals as a stock to watch closely in the coming weeks.

Conclusion

The notable 10.4% rise in open interest for Glenmark Pharmaceuticals Ltd. amid stable price action and strong technical indicators reflects a growing market interest and evolving positioning in the derivatives segment. While the broader market and sector showed weakness, Glenmark’s resilience and increased derivatives participation suggest bullish undertones. Investors should monitor these developments alongside fundamental updates and sector trends to make informed decisions in this mid-cap pharmaceutical stock.

Only Rs. 9,999 - Get MojoOne for 1 Year + 3 Months FREE (60% Off) Start Today